Boston-based Ginkgo Bioworks announced on 10 April 2024 an expansion of its partnership with global healthcare leader, Novo Nordisk. This extended collaboration, set to span five years, is targeting improving the manufacturing of Novo Nordisk’s medicines with a focus on chronic diseases including diabetes and obesity.
Ginkgo Bioworks, known for its expertise in cell programming and biosecurity, will bring its synthetic biology platform to optimize Novo Nordisk’s R&D pipeline for serious chronic diseases.
This news follows the 25 March 2024 announcement by Novo Nordisk of its acquisition of Cardior Pharmaceuticals for (up to) € 1.025B.